Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTEP is a research drug developed by Merck & Co. as a selective allosteric antagonist of the metabotropic glutamate receptor subtype mGluR5. It was identified through structure–activity relationship studies on an older mGluR5 antagonist MPEP and has since served as a lead compound for newer drugs. MTEP is more potent and selective than MPEP as an mGluR5 antagonist and produces neuroprotective, antidepressant, analgesic, and anxiolytic effects in animal models. It also reduces symptoms of morphine withdrawal and has anti-addictive effects against ethanol self-administration and the addictive effects of nicotine, cocaine, and methamphetamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine.